Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
Tibet Rhodiola Pharmaceutical Holding Co
Research & Development
Tibet Rhodiola Pharmaceutical Holding Co
Research & Development Peer Comparison
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
|
Research & Development
-¥14.8m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
Sinopharm Group Co Ltd
HKEX:1099
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
Research & Development
-¥2B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
Jointown Pharmaceutical Group Co Ltd
SSE:600998
|
Research & Development
-¥201.9m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
C
|
China National Medicines Corp Ltd
SSE:600511
|
Research & Development
-¥53m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
Huadong Medicine Co Ltd
SZSE:000963
|
Research & Development
-¥1.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
See Also
What is Tibet Rhodiola Pharmaceutical Holding Co's Research & Development?
Research & Development
-14.8m
CNY
Based on the financial report for Dec 31, 2023, Tibet Rhodiola Pharmaceutical Holding Co's Research & Development amounts to -14.8m CNY.
What is Tibet Rhodiola Pharmaceutical Holding Co's Research & Development growth rate?
Research & Development CAGR 5Y
-13%
Over the last year, the Research & Development growth was 82%. The average annual Research & Development growth rates for Tibet Rhodiola Pharmaceutical Holding Co have been -29% over the past three years , -13% over the past five years .